CD13/APN rescues angiogenesis in vivo.

Matrigel containing bFGF, heparin, and either the vehicle control (column 1) or the MEK inhibitor PD98059 (columns 2-4) plus functional CD13/APN-high (column 4) or control EOMA (column 3) membrane preparations were injected subcutaneously into mice. Plugs were harvested after 7 days and (A) examined for CD31⁺ (brown color, anti-CD31) endothelial-lined tubules and infiltration of inflammatory cells (top panel, original magnification × 10; bottom panel, original magnification × 40); or (B) angiogenesis quantitated by hemoglobin content.